SHINTAROU MIYAMOTO

Last Updated :2022/12/02

Affiliations, Positions
Hiroshima University Hospital(Patient Support Center), Associate Professor or Lecturer
E-mail
miyamoshiroshima-u.ac.jp

Basic Information

Major Professional Backgrounds

  • 2009/04/01, 2009/12/31, Hiroshima University, Hospital, Medical Staff
  • 2010/01/01, 2011/03/31, Hiroshima University, Hospital, Clinical Staff
  • 2011/04/01, 2012/03/31, Hiroshima University, Hospital, Clinical Fellow
  • 2012/04/01, 2015/03/31, Kochi University, Assistant Professor
  • 2015/04/01, 2017/12/31, Hiroshima University, Hospital, Assistant Professor
  • 2018/01/01, Hiroshima University Hospital, Lecturer

Educational Backgrounds

  • Hiroshima University, Graduate School of Biomedical Sciences, Japan, 2006/04, 2012/01
  • Hiroshima University, Faculty of Medicine, Japan, 1995/04, 2001/03

Academic Degrees

  • Hiroshima University

Educational Activity

  • [Bachelor Degree Program] School of Medicine : Program of Medicine : Medicine

Research Fields

  • Medicine,dentistry, and pharmacy;Clinical internal medicine;Respiratory organ internal medicine

Research Keywords

  • Respiratory Medicine
  • Allergology
  • Bronchial Asthma
  • Patient Safety

Educational Activity

Course in Charge

  1. 2022, Undergraduate Education, Year, Clinical diagnosis and treatment I
  2. 2022, Undergraduate Education, Intensive, Practice of Medicine I
  3. 2022, Undergraduate Education, Intensive, Practice of Medicine II

Research Activities

Academic Papers

  1. ★, Intra-airway administration of small interfering RNA targeting plasminogen activator inhibitor-1 attenuates allergic asthma in mice, Am J Physiol Lung Cell Mol Physiol, 301(6), L908-L916, 2011
  2. Comparative Study of Circulating MMP-7, CCL18, KL-6, SP-A, and SP-D as Disease Markers of Idiopathic Pulmonary Fibrosis, Disease Markers, 2016
  3. Characteristics of inspiratory and expiratory reactance in interstitial lung disease, Respir Med, 107, 875-882, 2013
  4. Cross-sectional and prospective study of the association between lung function and prediabetes, BMJ Open, 2013
  5. Seasonal variation of serum KL-6 concentrations is greater in patients with hypersensitivity pneumonitis, BMC Pulm Med, 7(14), 129, 2013
  6. Carboplatin plus Weekly Paclitaxel with Bevacizumab for First-line Treatment of Non-small Cell Lung Cancer, Anticancer Res, 36, 307-312, 2016
  7. Sputum Leucine-Rich Alpha-2 Glycoprotein as a Marker of Airway Inflammation in Asthma, PLoS One, 11(9), e0162672, 2016
  8. Chronic Intestinal Pseudo-obstruction and Orthostatic Hypotension Associated with Small Cell Lung Cancer that Improved with Tumor Reduction after Chemoradiotherapy, INTERNAL MEDICINE, 56(19), 2627-2631, 2017
  9. AGER rs2070600 polymorphism elevates neutrophil-lymphocyte ratio and mortality in metastatic lung adenocarcinoma, ONCOTARGET, 8(55), 94382-94392, 20171107
  10. Additional Octreotide Therapy to Sirolimus Achieved a Decrease in Sirolimus-refractory Chylous Effusion Complicated with Lymphangioleiomyomatosis, INTERNAL MEDICINE, 56(24), 3327-3331, 2017
  11. The extent of ground-glass attenuation is a risk factor of chemotherapy-related exacerbation of interstitial lung disease in patients with non-small cell lung cancer, CANCER CHEMOTHERAPY AND PHARMACOLOGY, 81(1), 131-139, 201801
  12. Nivolumab-induced severe pancytopenia in a patient with lung adenocarcinoma, LUNG CANCER, 119, 21-24, 201805
  13. Aminopeptidase N/CD13 as a potential therapeutic target in malignant pleural mesothelioma, EUROPEAN RESPIRATORY JOURNAL, 51(5), 20180501
  14. Bevacizumab with Single-agent Chemotherapy in Previously Treated Non-squamous Non-small-cell Lung Cancer: Phase II Study, IN VIVO, 32(5), 1155-1160, 2018
  15. Intratracheal Administration of siRNA Dry Powder Targeting Vascular Endothelial Growth Factor Inhibits Lung Tumor Growth in Mice, MOLECULAR THERAPY-NUCLEIC ACIDS, 12, 698-706, 20180907
  16. Plasminogen activator inhibitor-1 serves an important role in radiation-induced pulmonary fibrosis, EXPERIMENTAL AND THERAPEUTIC MEDICINE, 16(4), 3070-3076, 201810
  17. Alternate-day administration of S-1 for elderly patients with advanced non-small-cell lung carcinoma: A prospective feasibility study, MOLECULAR AND CLINICAL ONCOLOGY, 9(5), 539-544, 201811
  18. Serial measurements of KL-6 for monitoring activity and recurrence of interstitial pneumonia with anti-aminoacyl-tRNA synthetase antibody A retrospective cohort study, MEDICINE, 97(49), 201812
  19. Anti-KL-6/MUC1 monoclonal antibody reverses resistance to trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity by capping MUC1, CANCER LETTERS, 442, 31-39, 2019
  20. High preoperative C-reactive protein level is a risk factor for acute exacerbation of interstitial lung disease after non-pulmonary surgery, MEDICINE, 98(5), 201902
  21. Cerebral embolism during edoxaban administration for venous thromboembolism in a patient with lung adenocarcinoma A case report, MEDICINE, 98(12), 201903
  22. Inhibition of PAI-1 limits chemotherapy resistance in lung cancer through suppressing myofibroblast characteristics of cancer-associated fibroblasts, JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 23(4), 2984-2994, 201904
  23. Performance Status Is a Risk Factor for Depression before the Diagnosis of Lung Cancer Patients, INTERNAL MEDICINE, 58(7), 915-920, 2019
  24. Suplatast tosilate reduces radiation-induced lung injury in mice through suppression of oxidative stress, FREE RADICAL BIOLOGY AND MEDICINE, 136, 52-59, 20190520
  25. Comparison of anti-aminoacyl-tRNA synthetase antibody-related and idiopathic non-specific interstitial pneumonia, RESPIRATORY MEDICINE, 152, 44-50, 201906
  26. A Prospective Cohort Study to Define the Clinical Features and Outcome of Lung Cancers Harboring HER2 Aberration in Japan (HER2-CS STUDY), CHEST, 156(2), 357-366, 201908
  27. Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer, RESPIRATORY INVESTIGATION, 57(5), 451-459, 201909
  28. C-C Motif Chemokine Ligand 15 May Be a Useful Biomarker for Predicting the Prognosis of Patients with Chronic Hypersensitivity Pneumonitis, RESPIRATION, 98(3), 212-220, 201909
  29. Chemotherapy-associated Acute Exacerbation of Interstitial Lung Disease Shortens Survival Especially in Small Cell Lung Cancer, ANTICANCER RESEARCH, 39(10), 5725-5731, 201910
  30. Non-small Cell Lung Cancer Treated by an Anti-programmed Cell Death-1 Antibody without a Flare-up of Preexisting Granulomatosis with Polyangiitis, INTERNAL MEDICINE, 58(21), 3129-3132, 2019
  31. Albumin-globulin ratio is a predictive biomarker of antitumor effect of anti-PD-1 antibody in patients with non-small cell lung cancer, INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 25(1), 74-81, 202001
  32. Treatment rationale and design of the PROLONG study: safety and efficacy of pembrolizumab as first-line therapy for elderly patients with non-small cell lung cancer, JOURNAL OF THORACIC DISEASE, 12(3), 1079-1084, 202003
  33. Serum high-mobility group box 1 is associated with the onset and severity of acute exacerbation of idiopathic pulmonary fibrosis, RESPIROLOGY, 25(3), 275-280, 202003
  34. Reduced endogenous secretory RAGE in blood and bronchoalveolar lavage fluid is associated with poor prognosis in idiopathic pulmonary fibrosis, RESPIRATORY RESEARCH, 21(1), 20200611
  35. Sex-specific differences in the association between birth weight and lung volume in Japanese young adults., Respir Investig., 57, 598-604, 2019

Publications such as books

  1. 2007, Essentials of Mechanical Ventilation, Scholarly Book, Joint Translation

Invited Lecture, Oral Presentation, Poster Presentation

  1. Intra-airway Administration of Small Interfering RNA Targeting Plasminogen Activator Inhibitor – 1 Suppresses Allergic Airway Inflammation, Airway Hyperresponsiveness, And Airway Remodeling In a Murine Asthma Model, American Thoracic Society International Conference, 2010, Without Invitation, English, New Orleans
  2. Intra-airway administration of small interfering RNA targeting plasminogen activator inhibitor - 1 suppresses allergic asthma in a murine mode, European Respiratory Society Annual Congress, 2010, Without Invitation, English, Barcelona,
  3. The state of asthma control in asthmatics with gastro-esophageal reflux disease, 18th Interasma Japan/North Asia, 2008, Without Invitation, English, Osaka
  4. Decreased circulatory receptor for advanced glycation end-products is associated with poorer survival in patients with idiopathic pulmonary fibrosis, Kakuhiro Yamaguchi, Hiroshi Iwamoto, Yasushi Horimasu, Takeshi Masuda, Taku Nakashima, Shintaro Miyamoto, Shinichiro Ohshimo, Kazunori Fujitaka, Noboru Hattori, Witold Mazur, Nobuoki Kohno., 第56回日本呼吸器学会学術講演会, 2016/04/10, Without Invitation, English
  5. Airway reversibility assessed by oscillometry in patients with asthma, Higaki N, Iwamoto H, Horimasu Y, Masuda T, Miyamoto S, Nakashima T, Fjitaka K, Hamada H, Hattori N, ERS Milan 2017 International Congress, 2017/09/09, Without Invitation, English, Milan, Italy
  6. Vascular Endothelial Growth Factor Knockdown by Intratracheal administration of Small-Interfering RNA Dry Powder Inhibits Tumor Growth In a Mouse Lung Metastasis Model., Miwata K, Horimasu Y, Masuda T, Miyamoto S, Nakashima T, Iwamoto H, Fujitaka K, Hamada H, Hattori N, ATS 2018 International Conference, 2018/05/18, Without Invitation, English, San Diego
  7. Extent of the Honeycombing Area and the Presence of Traction Bronchiectasis are Risk Factors for Poorer Prognosis in Patients with Pleuroparenchymal Fibroelastosis., Namba M, Masuda T, Yamaguchi K, Sakamoto S, Horimasu Y, Miyamoto S, Nakashima T, Iwamoto H, Ohshimo S, Fujitaka K, Hamada H, Hattori N, ATS 2018 International Conference, 2018/05/18, Without Invitation, English, San Diego
  8. PAI-1 Influences the Effectiveness of Chemotherapy Through Its Association with Apoptosis in Cancer-Associated Myofibroblasts, Masuda T. Nakashima T, Namba M, Yamaguchi K, Sakamoto S, Horimasu Y, Miyamoto S, Iwamoto H, Fujitaka K, Hamada H, Hattori N, ATS 2018 International Conference, 2018/05/18, Without Invitation, English, San Diego
  9. Modified GAP stage as a predictor of acute exacerbation in idiopathic pulmonary fibrosis, Ohshimo S, Kida Y, Kyo M, Hosokawa K, Horimasu Y, Miyamoto S, Iwamoto H, Hamada H, Hattori N, Bonella F, Guzman J, Costabel U, Shime N, ERS International Congress 2018, 2018/09/15, Without Invitation, English, Paris
  10. Fine crackles quantitative value can help the diagnosis of interstitial lung diseases – Clinical utility of the innovative analyzing system of respiratory sounds, Horimasu Y, Ohshimo S, Yamaguchi K, Sakamoto S, Masuda T, Nakashima T, Miyamoto S, Iwamoto H, Sadamori T*, Fujitaka K, Hamada H, Shime N*, Hattori N., European Respiratory Society International Congress 2019, 2019/09/28, Without Invitation, English, Madrid
  11. Imbalance in the oral bacterial flora as a risk factor for acute exacerbation in idiopathic pulmonary fibrosis, Ohshimo S, Nishi H, Hosokawa K, Horimasu Y, Miyamoto S, Iwamoto H, Hamada H, Kawaguchi H, Bonella F, Guzman J, Costabel U, Hattori N, Shime N., European Respiratory Society International Congress 2019, 2019/09/28, Without Invitation, English, Madrid
  12. Serum high mobility group box 1 is associated with the onset and severity of acute exacerbation of idiopathic pulmonary fibrosis, Yamaguchi K, Iwamoto H, Sakamoto S, Horimasu Y, Masuda T, Miyamoto S, Nakashima T, Ohshimo S, Fujitaka K, Hamada H, Hattori N., European Respiratory Society International Congress 2019, 2019/09/28, Without Invitation, English, Madrid
  13. Clinical Utility of BALF CCL15 as a prognostic biomarker for Chronic Hypersensitivity Pneumonitis, Watanabe M,Horimasu Y, Iwamoto H, Yamaguchi K, Sakamoto S, Masuda T, Nakashima T, Miyamoto S, Ohshimo S, Fujitaka K, Hamada H, Kohno N, Hattori N., European Respiratory Society International Congress 2019, 2019/09/28, Without Invitation, English, Madrid
  14. Different aspects of diffuse lung diseases in intensive care unit and respiratory department, Ohshimo S, Kida Y, Hirano C, Kikutani K, Kyo M, Inagawa T, Ota K, Hosokawa K, Yamaguchi K, Horimasu Y, Miyamoto S, Iwamoto H, Fujitaka K, Hamada H, Bonella F, Guzman J, Costabel U*, Hattori N, Shime N., WASOG International conference on Sarcoidosis and Interstitial Lung Diseases 2019, 2019/10/09, Without Invitation, English, Yokohama
  15. Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer, Masuda T, Nakanishi Y, Yamaguchi K, Sakamoto S, Horimasu Y, Miyamoto S, Nakashima T, Iwamoto H, Fujitaka K, Hamada H, Hattori N., The 24th Congress of the Asian Pacific Society of Respirology (APSR 2019), 2019/11/14, Without Invitation, English, Hanoi
  16. The incidence and risk factors for acute exacerbation of interstitial lung disease after non-pulmonary surgery., Takao S, Masuda T, Yamaguchi K, Sakamoto S, Horimasu Y, Miyamoto S, Nakashima T, Iwamoto H, Fujitaka K, Hamada H, Hattori N., The 24th Congress of the Asian Pacific Society of Respirology (APSR 2019), 2019/11/14, Without Invitation, English, Hanoi
  17. Albumin-globulin ratio is a predictive biomarker of antitumor effect of anti-PD-1 antibody in patients with non-small cell lung cancer, Nakanishi Y, Masuda T, Sakamoto S, Yamaguchi K, Horimasu Y, Nakashima T, Miyamoto S, Iwamoto H, Fujitaka K, Hamada H, Hattori N., The 24th Congress of the Asian Pacific Society of Respirology (APSR 2019), 2019/11/14, Without Invitation, English, Hanoi
  18. EGFR gene mutation is not a significant risk factor in patients with EGFR mutated non-small cell lung cancer who receive best supportive care alone, Masuda T, Wakabayashi Y, Shimoji K, Yamaguchi K, Sakamoto S, Nishimura Y, Horimasu Y, Nakashima T, Miyamoto S, Senoo T, Iwamoto H, Ohshimo S, Fujitaka K, Hamada H, Hattori N., 2020 ASCO Annual Meeting, 2020/05/29, Without Invitation, English, Chicago
  19. Clinical significance of BIM deletion polymorphism on chemoradiotherapy in patients with non-small cell lung cancer, Wakabayashi Y, Masuda T, Nakashima T, Fujitaka K, Yamaguchi K, Sakamoto S, Nishimura Y, Horimasu Y, Miyamoto S, Senoo T, IwamotoH, Ohshimo S, Hamada H, Hattori N., 2020 ASCO Annual Meeting, 2020/05/29, Without Invitation, English, Chicago
  20. Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-NSCLC cancers., Shimoji K, Masuda T, Nakanishi Y, Yamaguchi K, Sakamoto S, Horimasu Y, Nakashima T, Miyamoto S, Iwamoto H, Fujitaka K, Hamada H, Hattori N., 2020 ASCO Annual Meeting, 2020/05/29, Without Invitation, English, Chicago
  21. Difference between pathogenic and inhibitory bacterial florae is associated with acute exacerbation of idiopathic pulmonary fibrosis, Ohshimo S, Nishi H, Yamaguchi K, Horimasu Y, Masuda T, Miyamoto S, Iwamoto H, Fujitaka K, Hamada H, Kawaguchi H, Bonella F, Guzman J, Costabel U, Hattori N, Shime N, 30th International Congress of the European Respiratory Society, 2020/09/05, Without Invitation, English, Vienna
  22. Increased fraction of small round lymphocyte in BALF is a diagnostic indicator for sarcoidosis, Horimasu Y, Yamaguchi K, Sakamoto S, Masuda T, Miyamoto S, Nakashima T, Iwamoto H, Fujitaka K, Hamada H, Hattori N, 30th International Congress of the European Respiratory Society, 2020/09/05, Without Invitation, English, Vienna
  23. Reduced endogenous secretory RAGE in blood and bronchoalveolar lavage fluid is associated with poor prognosis in idiopathic pulmonary fibrosis, Yamaguchi K, Iwamoto H, Mazur W, Miura S, Sakamoto S, Horimasu Y, Masuda T, Miyamoto S, Nakashima T, Ohshimo S, Fujitaka K, Hamada H, Hattori N, 30th International Congress of the European Respiratory Society, 2020/09/05, Without Invitation, English
  24. IL-18 binding protein can be a prognostic biomarker for idiopathic pulmonary fibrosis, Nakanishi Y, Horimasu Y, Yamaguchi K, Sakamoto S, Masuda T, Nakashima T, Miyamoto S, Iwamoto H, Ohshimo S, Fujitaka K, Hamada H, Hattori N, 30th International Congress of the European Respiratory Society, 2020/09/05, Without Invitation, English, Vienna
  25. Pivotal role of the HMGB1/sRAGE axis in drug-induced lung injury in advanced lung cancer with pre-existing interstitial lung disease, Nakao S, Yamaguchi K, Sakamoto S, Horimasu Y, Masuda T, Miyamoto S, Nakashima T, Iwamoto H, Ohshimo S, Fujitaka K, Hamada H, Hattori N, 30th International Congress of the European Respiratory Society, 2020/09/05, Without Invitation, English, Vienna
  26. Correlations of forced oscillometric bronchodilator response with airway inflammation and disease duration in asthma, Higaki N, Iwamoto H, Yamaguchi K, Sakamoto S, Horimasu Y, Masuda T, Miyamoto S, Nakashima T, Fujitaka K, Hamada H, Hattori N, JSA/WAO Joint Congress 2020, 2020/09/17, Without Invitation, English, Kyoto
  27. Real-world study of prescription pattern of inhaled corticosteroids in adult asthma, Nakanishi Y, Iwamoto H, Nakao S, Higaki N, Yamaguchi K, Sakamoto S, Horimasu Y, Masuda T, Matsumoto N, Nakashima T, Miyamoto S, Onari Y, Fujitaka K, Haruta Y, Hamada H, Hozawa S, Hattori N, JSA/WAO Joint Congress 2020, 2020/09/17, Without Invitation, English, Kyoto
  28. Decline of lung function in adults with a history of childhood asthma, Miura S, Iwamoto H, Omori K, Yamaguchi K, Sakamoto S, Horimasu Y, Masuda T, Miyamoto S, Nakashima T, Fujitaka K, Hamada H, Yokoyama A, Hattori N., JSA/WAO Joint Congress 2020, 2020/09/17, Without Invitation, English, Kyoto
  29. Autoantibody positivity is a risk factor for chemotherapy-induced exacerbation of interstitial pneumonia in lung cancer, Ito N, Masuda T, Yamaguchi K, Sakamoto S, Horimasu Y, Miyamoto S, Nakashima T, Iwamoto H, Fujitaka K, Hamada H, Hattori N, The 25th Congress of the Asian Pacific Society of Respirology, 2021/11/20, Without Invitation, English, Kyoto
  30. The role of circulatory high-mobility group box 1 for predicting checkpoint inhibitor pneumonitis caused by anti-PD-1/PD-L1 antibody monotherapy, Yamaguchi K, Tanahashi H, Kurose K, Nakao S, Sakamoto S, Horimasu Y, Masuda T, Miyamoto S, Nakashima T, Iwamoto H, Fujitaka K, Hamada H, Oga T, Oka M, Hattori N, The 25th Congress of the Asian Pacific Society of Respirology, 2021/11/20, Without Invitation, English, Kyoto
  31. Antifibrotic effect of lung-resident progenitor cells with high aldehyde dehydrogenase activity, Takahashi H, Nakashima T, Masuda T, Namba M, Sakamoto S, Yamaguchi K, Horimasu Y, Miyamoto S, Iwamoto H, Fujitaka K, Hamada H, Hattori N, The 25th Congress of the Asian Pacific Society of Respirology, 2021/11/20, Without Invitation, English, Kyoto
  32. Clinical characteristics of Preserved Ratio Impaired Spirometry in Japan, Miura S, Iwamoto H, Omori K, Yamaguchi K, Sakamoto S, Horimasu Y, Masuda T, Miyamoto S, Nakashima T, Fujitaka K, Hamada H, Yokoyama A, Hattori N, The 25th Congress of the Asian Pacific Society of Respirology, 2021/11/20, Without Invitation, English, Kyoto
  33. A case of pulmonary alveolar proteinosis with severe respiratory failure improved by segmental lung lavage with fiberoptic bronchoscopy under general anesthesia, Matsumoto Y, Masuda T, Takahashi H, Hashimoto K, Yamaguchi K, Sakamoto S, Horimasu Y, Nakashima T, Miyamoto S, Iwamoto H, Ohshimo S, Fujitaka K, Yamasaki M, Hamada M, Hattori N, The 25th Congress of the Asian Pacific Society of Respirology, 2021/11/20, Without Invitation, English, Kyoto
  34. The associations between patients' preference for inhaled medications and asthma control, Nakanishi Y, Iwamoto H, Miyamoto S, Nakao S, Higaki N, Yamaguchi K, Sakamoto S, Horimasu Y, Masuda T, Matsumoto N, Nakashima T, Onari Y, Fujitaka K, Haruta Y, Hamada H, Hozawa S, Hattori N, The 25th Congress of the Asian Pacific Society of Respirology, 2021/11/20, Without Invitation, English, Kyoto

External Funds

Acceptance Results of Competitive Funds

  1. KAKENHI(Grant-in-Aid for Early-Career Scientists), 2019, 2022
  2. 2013/04/01, 2016/03/31
  3. 2019/04/01, 2020/03/31
  4. 2020/04/01, 2021/03/31